-
ce.effectivehealthcare.ahrq.gov/sites/default/files/2024-02/zierler-report.pdf
January 01, 2024 - For special cases, such as pregnant women or patients with
allergies to contrast dye, the investigators
-
www.cpsi.ahrq.gov/sites/default/files/wysiwyg/teamstepps/longtermcare/essentials/ts2-0ltc_essentials_ig.pdf
July 11, 2017 - changes, response to
treatment
S Safety Concerns—Critical lab values/reports,
socioeconomic factors, allergies
-
ce.effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/teamstepps/longtermcare/essentials/ts2-0ltc_essentials_ig.pdf
July 11, 2017 - changes, response to
treatment
S Safety Concerns—Critical lab values/reports,
socioeconomic factors, allergies
-
preventiveservices.ahrq.gov/teamstepps/instructor/essentials/igessentials.html
March 01, 2019 - S = Safety Concerns —Critical lab values/reports, socio-economic factors, allergies, alerts (falls,
-
preventiveservices.ahrq.gov/sites/default/files/wysiwyg/professionals/education/curriculum-tools/teamstepps/instructor/essentials/igessentials.pdf
March 11, 2014 - response to
treatment
S Safety Concerns—Critical lab values/reports, socio-
economic factors, allergies
-
ce.effectivehealthcare.ahrq.gov/teamstepps/instructor/essentials/igessentials.html
March 01, 2019 - S = Safety Concerns —Critical lab values/reports, socio-economic factors, allergies, alerts (falls,
-
ce.effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/professionals/education/curriculum-tools/teamstepps/instructor/essentials/igessentials.pdf
March 11, 2014 - response to
treatment
S Safety Concerns—Critical lab values/reports, socio-
economic factors, allergies
-
www.ahrq.gov/sites/default/files/wysiwyg/professionals/education/curriculum-tools/teamstepps/instructor/essentials/igessentials.pdf
March 11, 2014 - response to
treatment
S Safety Concerns—Critical lab values/reports, socio-
economic factors, allergies
-
ce.effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/professionals/quality-patient-safety/patient-safety-resources/resources/advances-in-patient-safety-2/vol3/Advances-Seagull_98.pdf
April 07, 2008 - cross-checks drugs and blood products brought into the room, ensuring
patient compatibility in terms of allergies
-
www.ahrq.gov/sites/default/files/wysiwyg/teamstepps/longtermcare/essentials/ts2-0ltc_essentials_ig.pdf
July 11, 2017 - changes, response to
treatment
S Safety Concerns—Critical lab values/reports,
socioeconomic factors, allergies
-
www.ahrq.gov/sites/default/files/wysiwyg/professionals/quality-patient-safety/patient-safety-resources/resources/advances-in-patient-safety-2/vol3/Advances-Seagull_98.pdf
April 07, 2008 - cross-checks drugs and blood products brought into the room, ensuring
patient compatibility in terms of allergies
-
digital.ahrq.gov/sites/default/files/docs/publication/r18hs017094-mccolm-final-report-2009.pdf
January 01, 2009 - Standardization included provider documentation templates, electronic
prescribing and documentation of allergies
-
www.ahrq.gov/sites/default/files/2024-02/zierler-report.pdf
January 01, 2024 - For special cases, such as pregnant women or patients with
allergies to contrast dye, the investigators
-
psnet.ahrq.gov/perspective/what-have-we-learned-about-safe-inpatient-handovers
March 01, 2011 - Administrative information, diagnoses, current medications, and allergies, as well as an editable synopsis
-
digital.ahrq.gov/sites/default/files/docs/citation/r21hs025005-snyder-final-report-2019.pdf
January 01, 2019 - (i.e., drug–drug interaction vs. allergy alert vs. possible medication non-
adherence)
5ii
5iii … what might happen if the alert is ignored;
(medical or patient care consequences, for example, the allergic … reaction that may occur if
the instruction information is ignored.)
6v Does the alert minimize
-
www.ahrq.gov/sites/default/files/publications/files/cdifftoolkit.pdf
September 01, 2012 - hepatitis;
hemolytic anemia in G6PD
deficiency
Cefuroxime 250 mg oral
q12h
Avoid in penicillin allergy … ;
interstitial nephritis;
hemolytic anemia
Cefpodoxime 100 mg oral
q12h
Avoid in penicillin allergy … Effects
(selected)
Initial Therapy
Ceftriaxone 1 g IV/IM 1
st
dose
Avoid in serious, type-I
PCN allergy
-
ce.effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/professionals/quality-patient-safety/patient-safety-resources/resources/advances-in-patient-safety-2/vol3/Advances-Woods_78.pdf
July 23, 2008 - remind and support memory, check calculations, limit
dosages, and bring forward information (e.g., an allergy
-
effectivehealthcare.ahrq.gov/sites/default/files/cer-221-copd-evidence-summary.pdf
October 01, 2019 - Immunol Allergy Clin North
Am. 2013 Feb;33(1):95-115.
doi: 10.1016/j.iac.2012.10.006.
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/mental-health-mobile-apps-disposition-of-comments.pdf
May 20, 2022 - that each medication type can serve a different
purpose from the other (i.e., antihypertensive vs. allergy
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/mental-health-mobile-apps-disposition-of-comments.pdf
May 20, 2022 - that each medication type can serve a different
purpose from the other (i.e., antihypertensive vs. allergy